Allergan, Ironwood Seek To Divide And Conquer IBS With New Linzess Formulations
Executive Summary
Allergan and Ironwood Pharmaceuticals are beefing up the blockbuster potential of their IBS drug Linzess with two new formulations that target different disease populations showing promising Phase II data. Further Phase IIb and III trials are now in the offing.
You may also be interested in...
Ironwood Puts It Bluntly: Denner Lacks Case To Join Board, Wouldn’t Provide Missing Insight
Citing concerns that Linzess might not hit the blockbuster threshold by 2020, as predicted by Ironwood, one analyst lowers the firm’s stock rating on the same day the company clarifies that it does not want activist investor Alex Denner to join its board.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.